We aimed to assess the oncological impact of micrometric extent of invasion in patients with pT1 bladder cancer (BCa) who underwent en-bloc resection for bladder tumour (ERBT).
We retrospectively analysed the records and specimens of 106 pT1 high-grade BCa patients who underwent ERBT. The extent of invasion, such as depth from basal membrane, number of invasive foci, maximum width of invasive focus, muscularis mucosae invasion and infiltration pattern (pattern A: solid sheet-like, nodular or nested growth, pattern B: trabecular, small cluster or single-cell pattern) were evaluated by a single genitourinary pathologist. The end-points were recurrence-free (RFS) and progression-free survival (PFS). Within a median follow-up of 23 months, overall, 36 patients experienced recurrence and 13 patients experienced disease progression. The 2-year PFS differed significantly depending on depth from basal membrane (< 1.3 mm: 94.8% versus ≧ 1.3 mm: 65.2%, P = 0.005), maximum width of invasive focus (< 4 mm: 91.7% versus ≧ 4 mm: 62.3%, P < 0.001), muscularis mucosae (MM) invasion (above MM = 96.1% versus into or beyond MM = 64.8%, P = 0.002) and infiltration pattern (pattern A: 100% versus pattern B: 83.3%, P = 0.037). In a multivariable analysis, MM invasion [hazard ratio (HR) = 4.54, 95% confidence interval (CI) = 1.25-16.5] and maximum width of invasive focus ≧ 4 mm (HR = 4.79, 95% CI = 1.25-16.5) were independent prognostic factors of progression.
En-bloc resection facilitates the evaluation of pathologic variables that might be useful in predicting disease recurrence and progression. In particular, not only the MM invasion but also the maximum width of invasion focus, reflecting the invasive volume, appear to be reliable prognosticators for disease progression.
Histopathology. 2024 Mar 13 [Epub ahead of print]
Takafumi Yanagisawa, Shun Sato, Yasushi Hayashida, Yohei Okada, Akihiro Matsukawa, Kosuke Iwatani, Masayuki Shimoda, Hiroyuki Takahashi, Takahiro Kimura, Shahrokh F Shariat, Jun Miki
Department of Urology, The Jikei University School of Medicine, Tokyo, Japan., Department of Pathology, The Jikei University School of Medicine, Tokyo, Japan., Department of Urology, National Hospital Organization Ureshino Medical Center, Saga, Japan., Department of Urology, Saitama Medical Center, Saitama, Japan., Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria.